Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

AML with Translocation T(8;16) Shows Unique Cytomorphological, Cytogenetic, Molecular, and Prognostic Features and Therefore Qualifies as An Own Entity According to WHO Criteria.

Alexander Kohlmann, PhD, Martin Dugas, MD, Hans-Ulrich Klein, Christian Ruckert, Wolfgang Kern, MD, Susanne Schnittger, PhD, Helmut Löffler, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2008) 112 (11): 1197.

https://doi.org/10.1182/blood.V112.11.1197.1197

Published: 2008

Journal Articles

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

Wolfgang Kern, Torsten Haferlach, Claudia Schoch, Helmut Löffler, Winfried Gassmann, Achim Heinecke, Maria Christina Sauerland, Wolfgang Berdel, Thomas Büchner, Wolfgang Hiddemann

Blood (2003) 101 (1): 64–70.

https://doi.org/10.1182/blood-2002-02-0532

Published: 2003

Journal Articles

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease: Presented in part at the 42nd annual meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA (abstract 3569).

Susanne Schnittger, Claudia Schoch, Martin Dugas, Wolfgang Kern, Peter Staib, Christian Wuchter, Helmut Löffler, Cristina Maria Sauerland, Hubert Serve, Thomas Büchner, Torsten Haferlach, Wolfgang Hiddemann

Blood (2002) 100 (1): 59–66.

https://doi.org/10.1182/blood.V100.1.59

Published: 2002

Journal Articles

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

Blood (1999) 94 (11): 3668–3677.

https://doi.org/10.1182/blood.V94.11.3668

Published: 1999

Journal Articles

Double Induction Strategy for Acute Myeloid Leukemia: The Effect of High-Dose Cytarabine With Mitoxantrone Instead of Standard-Dose Cytarabine With Daunorubicin and 6-Thioguanine: A Randomized Trial by the German AML Cooperative Group

Thomas Büchner, Wolfgang Hiddemann, Bernhard Wörmann, Helmut Löffler, Winfried Gassmann, Torsten Haferlach, Christa Fonatsch, Detlef Haase, Claudia Schoch, Dieter Hossfeld, Eva Lengfelder, Carlo Aul, Axel Heyll, Georg Maschmeyer, Wolf-Dieter Ludwig, Maria-Cristina Sauerland, Achim Heinecke

Blood (1999) 93 (12): 4116–4124.

https://doi.org/10.1182/blood.V93.12.4116

Published: 1999

Journal Articles

Immunophenotypic and Genotypic Features, Clinical Characteristics, and Treatment Outcome of Adult Pro-B Acute Lymphoblastic Leukemia: Results of the German Multicenter Trials GMALL 03/87 and 04/89

Blood (1998) 92 (6): 1898–1909.

https://doi.org/10.1182/blood.V92.6.1898

Published: 1998

Journal Articles

Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect

Bertram Glass, Lutz Uharek, Matthias Zeis, Peter Dreger, Helmut Löffler, Jörg Steinmann, Norbert Schmitz

Blood (1997) 90 (4): 1694–1700.

https://doi.org/10.1182/blood.V90.4.1694

Published: 1997

NARROW

AML with Translocation T(8;16) Shows Unique Cytomorphological, Cytogenetic, Molecular, and Prognostic Features and Therefore Qualifies as An Own Entity According to WHO Criteria.

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

Double Induction Strategy for Acute Myeloid Leukemia: The Effect of High-Dose Cytarabine With Mitoxantrone Instead of Standard-Dose Cytarabine With Daunorubicin and 6-Thioguanine: A Randomized Trial by the German AML Cooperative Group

Immunophenotypic and Genotypic Features, Clinical Characteristics, and Treatment Outcome of Adult Pro-B Acute Lymphoblastic Leukemia: Results of the German Multicenter Trials GMALL 03/87 and 04/89

Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect

Email alerts

ASH Publications

American Society of Hematology

AML with Translocation T(8;16) Shows Unique Cytomorphological, Cytogenetic, Molecular, and Prognostic Features and Therefore Qualifies as An Own Entity According to WHO Criteria.

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

Double Induction Strategy for Acute Myeloid Leukemia: The Effect of High-Dose Cytarabine With Mitoxantrone Instead of Standard-Dose Cytarabine With Daunorubicin and 6-Thioguanine: A Randomized Trial by the German AML Cooperative Group

Immunophenotypic and Genotypic Features, Clinical Characteristics, and Treatment Outcome of Adult Pro-B Acute Lymphoblastic Leukemia: Results of the German Multicenter Trials GMALL 03/87 and 04/89

Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only